Avadel Pharmaceuticals PLC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
Avadel Pharmaceuticals' Chief Operating Officer, Susan Rodriguez, disposed of 300,000 stock options as part of the company's acquisition by Alkermes plc.
Avadel Pharmaceuticals plc director Peter J. Thornton reports the disposition of all shares and options following the company's acquisition by Alkermes plc for $21.00 cash plus a contingent value right per share.
Avadel Pharmaceuticals General Counsel Jerad Seurer disposed of ordinary shares and stock options following the company's acquisition by Alkermes plc.
Avadel Pharmaceuticals plc shareholders receive $21.00 cash and a $1.50 CVR per share as Alkermes plc completes its acquisition.
Avadel Pharmaceuticals CFO Thomas S. McHugh disposed of all ordinary shares and stock options following the company's acquisition by Alkermes plc for $21.00 cash plus a contingent value right per share.
Avadel Pharmaceuticals director Mark Anthony McCamish disposed of all his direct and indirect ordinary shares and stock options as part of Alkermes plc's acquisition of Avadel.
Avadel Pharmaceuticals director Geoffrey Glass disposed of all his shares and options following the company's acquisition by Alkermes for $21 cash plus a CVR per share.
Avadel Pharmaceuticals director Eric J. Ende disposed of ordinary shares and stock options as part of Alkermes plc's acquisition of the company.
Avadel Pharmaceuticals CEO Gregory J. Divis disposed of all his ordinary shares and stock options as part of Alkermes plc's acquisition of Avadel.
Naseem Amin, a director at Avadel Pharmaceuticals, disposed of ordinary shares and stock options following the company's acquisition by Alkermes plc.
AVADEL Pharmaceuticals PLC Director Mark Anthony McCamish reported a future transfer of 67,025 ordinary shares to a charitable remainder trust.
AVADEL Pharmaceuticals PLC Director Linda Palczuk transferred 11,000 stock options with an exercise price of $10.83 to a revocable trust on September 15, 2025.
AVADEL PHARMACEUTICALS PLC Director Geoffrey Michael Glass transferred 11,000 stock options with an exercise price of $10.83 to a revocable trust on September 15, 2025.
Avadel Pharmaceuticals PLC Director Mark Anthony McCamish received 11,000 restricted ordinary shares and 11,000 stock options, vesting based on continued service.
Avadel Pharmaceuticals PLC Director Linda Palczuk was granted 11,000 restricted ordinary shares and 11,000 stock options, with vesting scheduled for July 2026 or the next annual general meeting.
Avadel Pharmaceuticals PLC Director Peter J. Thornton was granted 11,000 restricted ordinary shares and 11,000 stock options on July 29, 2025, as part of his compensation.
Avadel Pharmaceuticals PLC Director Geoffrey Michael Glass was granted 11,000 restricted ordinary shares and 11,000 stock options as part of his compensation, vesting over approximately one year.
Avadel Pharmaceuticals PLC Director Eric J. Ende was granted 11,000 restricted ordinary shares and 11,000 stock options, aligning his interests with shareholders.
Avadel Pharmaceuticals director Naseem Amin was granted 11,000 restricted ordinary shares and 11,000 stock options, with the transaction dated July 29, 2025.
Susan Rodriguez, Chief Operating Officer of Avadel Pharmaceuticals, was granted stock options to purchase 300,000 ordinary shares on May 13, 2025.
Jerad G. Seurer, General Counsel & Corporate Secretary of Avadel Pharmaceuticals, reports acquisition of restricted shares and stock options.
Form 4: Avadel Pharmaceuticals CFO Thomas McHugh Reports Stock Option Grant and Restricted Share Award
Chief Financial Officer of Avadel Pharmaceuticals, Thomas McHugh, reports the acquisition of stock options and a restricted share award.
CEO Gregory J. Divis Jr. of Avadel Pharmaceuticals reports acquisition of restricted shares and stock options, along with disposal of ordinary shares.
Director Linda Palczuk reports transferring 25,000 stock options to a revocable trust.
Director Linda Palczuk purchased 5,000 ordinary shares of Avadel Pharmaceuticals at a price of $7.928 per share on January 21, 2025.
Director Peter J. Thornton acquired 10,000 ordinary shares of Avadel Pharmaceuticals at a price of $8.045 per share on January 13, 2025.
Director Eric J. Ende purchased 30,000 ordinary shares of Avadel Pharmaceuticals PLC at a weighted average price of $7.8406 on January 13, 2025.
Director Linda Palczuk reported a disposition of 3,500 ordinary shares of Avadel Pharmaceuticals on December 24, 2024.
Director Linda Palczuk of Avadel Pharmaceuticals PLC acquired 25,000 stock options on December 17, 2024, according to a recent SEC filing.
Avadel Pharmaceuticals' Chief Financial Officer, Thomas S. McHugh, purchased 2,300 ordinary shares at a weighted average price of $10.4429 per share.